Semaglutide is a GLP-1 receptor agonist, which helps to regulate blood sugar by enhancing insulin secretion, slowing gastric emptying, and promoting satiety
Those who do not experience the intended results would not be a good candidate to continue the medication
semaglutide Semaglutide Drug Names : Ozempic (for T2DM) - injectable Wegovy (for weight management) - injectable Rybelsus (oral) - 1st oral GLP-1 agonist (FDA approved 9/20/19) Drug Category : GLP-1 receptor agonist, hypoglycemic Synthetic peptide analog of GLP-1 Mechanism of Action: Synthetic peptide that is chemically identical to GLP-1, except for three amino acid substitutions and modifications at positions 8, 26 & 34 (Figure 1) that prevent chemical breakdown by DPP-4, and increase binding to albumin
For people who find semaglutide side effects intolerable, switching from semaglutide to tirzepatide is an option that some providers recommend
Novo Nordisk said in a statement that the introduction generics in Canada was a "localized situation based on our specific patent timelines and regulatory environment and does not reflect the situation in the United States, where exclusivity remains intact"
